Recombinant adeno-associated viral

Yang, Y.-W. and Kotin, R.M. (2000) Glucose-responsive gene delivery in pancreatic islet cells via recombinant adeno-associated viral vectors. Pharm. Res., 17,1056-1060. 

J. F. Zhou, E.F. Vanin, and A.W. Nienhuis. 2001. Factors influencing in vivo transduction by recombinant adeno-associated viral vectors expressing the human factor IX cDNA. Blood 97 1258-1265. 

Clark, K. R., Sferra, T. J. and Johnson, P. R. (1997). Recombinant adeno-associated viral vectors mediate long-term transgene expression in muscle. Hum. Gene Ther. 8, 659-669. 

Mathews, L. C., Gray, J. T., Gallagher, M. R. and Snyder, R. O. (2002). Recombinant adeno-associated viral vector production using stable packaging and producer cell lines. Methods Enzymol. 346, 393-413. 

Snyder, R. O., Xiao, X. and Samulski, R. J. (1996). Production of recombinant adeno-associated viral vectors. In Current Protocols in Human Genetics (Dracopoli, N., ed.). John Wiley and Sons, New York, pp. 12.1.1-24. 

Zolotukhin, S. et al. (2002). Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. Methods 28, 158-167. 

Kapturczak, M., Zolotukhin, S., Cross, J., Pileggi, A., Molano, R. D., Jorgensen, M., Byrne, B., Flotte, T., Ellis, T. R., Inverardi, L., Ricordi, C., Nick, H., Atkinson, M. and Agarwal, A. (2002). Transduction of human and mouse pancreatic islet cells using a bicistronic recombinant adeno-associated viral vector. Mol. Ther. J, 154-160. 

Eslamboli, A. et al. (2003). Recombinant adeno-associated viral vector (rAAV) delivery of GDNF provides protection against 6-OHDA lesion in the common marmoset monkey (Callithrix jacchus). Exp. Neurol. 184(1), 536-548. 

Leff, S. E. et al. (1999). Long-term restoration of striatal L-aromatic amino acid decarboxylase activity using recombinant adeno-associated viral vector gene transfer in a rodent model of Parkinson s disease. Neuroscience 92 (1), 185-196. 

Mandel, R. J. et al. (1999a). Progress in direct striatal delivery of L-dopa via gene therapy for treatment of Parkinson s disease using recombinant adeno-associated viral vectors. Exp. Neurol. 159(1), 47-64. 

Greelish, J. P., Su, L. T., Lankford, E. B. et al. (1999). Stable restoration of the sarcoglycan complex in dystrophic muscle perfused with histamine and a recombinant adeno-associated viral vector. Nat. Med. 5(4), 439-443. 

Shen F, Su H, Liu W, Kan YW, Young WL, Yang GY. Recombinant adeno-associated viral vector encoding human VEGF165 induces neomicrovessel formation in the adult mouse brain. Front Biosci 2006 11 3190-3198. 

Aikawa R, Huggins GS, Snyder RO. Cardiomyocyte-specific gene expression following recombinant adeno-associated viral vector transduction. J Biol Chem 2002 277 18979-18985. 

Earson D, Harding TC, Tao L, Liu J, Powell S, Vimal V, Yendluri S, Koprivnikar K, Ho K, Twitty C, Husak P, Lin A, Snyder RO, Donahue BA. Development and characterization of a ceU line for large-scale, serum-free production of recombinant adeno-associated viral vectors. J Gene Med 2004 6 1369-1381. 

Francis JD, Snyder RO. Production of research and clinical grade recombinant adeno-associated viral vectors. In Bems KI, Flotte TR (eds) Laboratory techniques in biochemistry and molecular biology. Elsevier, Amsterdam, 2005 19-56. 

---